New hope for nerve disease: immune therapy trial targets long-term control
NCT ID NCT06752356
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 6 times
Summary
This study tests two different doses of an intravenous immune globulin (IGIV 10%) as maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder causing weakness and numbness. About 161 participants will receive either a higher or lower dose for 24 weeks to see which better improves disability scores. The goal is to control the disease long-term, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Neurology Epilepsy and Sleep Center/ANESC Research
RECRUITINGEl Paso, Texas, 79912, United States
-
Dartmouth-Hitchcock Medical Center
RECRUITINGLebanon, New Hampshire, 03756, United States
-
USF Health - Morsani Center for Advanced Healthcare
RECRUITINGTampa, Florida, 33613, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new antibody calm the immune attack in CIDP?
- Could a simple blood test track nerve damage? a study investigates NT-3 levels in neuropathy.
- New drug mimics natural protein to calm overactive immune system in nerve disease
- Shocking muscles to move: new exercise hope for nerve disease patients
- Could a stem cell transplant stop the immune system from attacking the brain?
- Engineered immune cells take on multiple sclerosis and other nerve diseases